141 results about "Intraperitoneal route" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of hepcidin expression quantity in larimichthys crocea liver as larimichthys crocea visceral white-spot disease resistance evaluation index and a construction method. The hepcidin expression quantity in the larimichthys crocea liver is applied as the larimichthys crocea visceral white-spot disease resistance evaluation index. The construction method of the resistance evaluation index comprises the following steps: taking healthy small yellow croaker intraperitoneal injection pseudomonas proteinus strain bacterial liquid, and determining a half lethal dose in 96 hours; the method comprises the following steps: injecting a half lethal dose of bacterial liquid of pseudomonas proteinus strains into the abdominal cavity of healthy small yellow croaker for 96 hours, and after infection, taking different tissues to carry out hepcidin gene expression fluorescent quantitative PCR analysis; a regression model of gene expression quantity and bacterium loading quantity is established through fluorescence quantification, and the relationship between hepcidin expression quantity and disease resistance is constructed. Accurate disease-resistant phenotype information is provided for development of breeding of visceral white-spot disease-resistant improved varieties of the small yellow croakers, the accuracy of disease-resistant breeding is promoted, early detection of diseases is realized, and prevention and treatment of the diseases are effectively guided.

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The invention belongs to the field of biotechnology and aquaculture, and particularly relates to a method for improving hypoxia resistance of pelteobagrus vachelli based on hypoxia induction of liver extracellular vesicles of the pelteobagrus vachelli. The method comprises the following steps: extracting high-purity extracellular vesicles EVs in liver tissues of pelteobagrus vachelli subjected to low-oxygen treatment by adopting a method of combining differential centrifugation and high-precision iodixanol density gradient centrifugation; diluting the extracted EVs to 2mu g / mu L by using PBS (Phosphate Buffer Solution) to prepare an EVs suspension; an intraperitoneal injection mode is adopted, the EVs suspension is injected into the body of the pelteobagrus vachelli, and after injection is conducted for 24 hours, the hypoxia resistance of the pelteobagrus vachelli is evaluated through a suffocation point detection test. The invention opens up a brand new path for improving the hypoxia resistance of the pelteobagrus vachelli, provides a new idea and a new method for efficiently enhancing the hypoxia resistance of economic fishes in the field of aquaculture, is expected to play an important role in actual aquaculture production, and assists the sustainable development of the aquaculture industry.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention relates to the technical field of laboratory devices, in particular to an intelligent intraperitoneal injection auxiliary fixing device for laboratory mice, which comprises a basic bearing module, and a mouse fixing module, a pressure monitoring module, a control module, an indication module and a power supply module which are mounted on the basic bearing module, wherein the mouse fixing module is used for fixing a mouse, the mouse fixing module comprises a lower arc-shaped latticed clamping plate, an upper arc-shaped clamping plate, a connecting piece and a hook lock, the lower arc-shaped latticed clamping plate and the upper arc-shaped clamping plate are connected through the connecting piece, and the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate are jointly matched to clamp the mouse; the abdomen of the mouse faces the lower arc-shaped latticed clamping plate, the hook lock is used for fixing the upper arc-shaped clamping plate and the lower arc-shaped latticed clamping plate, the pressure monitoring module can monitor the stress condition of the mouse in real time, compressive stress or suffocation of the mouse is avoided, and animal welfare is improved.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses application of gnetum alcohol in treatment of adriamycin cardiomyopathy and diseases caused by adriamycin cardiomyopathy. The invention provides the application of the Gnetol or the pharmaceutically acceptable salt thereof in preparation of the medicine for preventing or treating diseases caused by adriamycin cardiomyopathy for the first time. The invention finds that in-vitro treatment of Gnemol can obviously inhibit rat H9C2 myocardial cell injury; when intraperitoneal injection of Gnetol is used for preventing or treating mice with adriamycin cardiomyopathy caused by intraperitoneal injection of adriamycin, the Gnetol is found to obviously relieve the adriamycin cardiotoxicity of the mice and improve the cardiac function. In-vitro and in-vivo studies find that Gnerol has a huge potential in treatment of adriamycin cardiomyopathy, and can be developed as a novel anti-adriamycin cardiomyopathy drug, thereby providing a novel approach and means for treatment of adriamycin cardiomyopathy. Meanwhile, the invention provides a brand new choice and thought for the current anti-adriamycin cardiomyopathy medicine.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention provides an application of combination of IL-28A and Anti-PD-1 antibodies in preparation of colon cancer drugs, and belongs to the technical field of biological medicines. The invention provides an application of IL-28A in preparation of an Anti-PD-1 antibody immune checkpoint sensitizer, and provides an application of combination of the IL-28A and an Anti-PD-1 antibody in preparation of a medicine for treating colon cancer. Through an intraperitoneal injection method, the result shows that the tumor can be gradually reduced and finally disappears when the IL-28A and the Anti-PD-1 are combined for treating the subcutaneous MC38 tumor of a mouse, and a remarkable synergistic effect can be generated when the IL-28A and the Anti-PD-1 antibody are combined for medication, so that the regression of the colon cancer tumor is facilitated.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The invention belongs to the field of biological medicine, particularly discloses pharmaceutical application of a Dio3 inhibitor screened based on a thyroid hormone disorder algorithm in sepsis cardiomyopathy, and discloses that the core pathological mechanism of SIC is thyroid hormone signal axis disorder caused by Dio3 abnormal up-regulation, further mitochondrial autophagy key protein is inhibited, and the application of the Dio3 inhibitor in sepsis cardiomyopathy is developed for the first time. And myocardial mitochondrial homeostasis imbalance and functional cardiac dysfunction are caused. Through single intraperitoneal injection (25mg / kg) of a compound PBENZ-DBRMD (specific Dio3 inhibitor) within 12 hours after sepsis occurs, heart function indexes (EF% / FS%) can be remarkably recovered, and mitochondrial autophagy disorder can be reversed. Meanwhile, serum transT3 (rT3) is provided as an SIC early diagnosis marker (rT3 is strongly negatively correlated with EF%). The scheme provides a new targeted intervention strategy for SIC, and has the characteristics of simplicity and convenience in operation and definite curative effect.

The invention belongs to the technical field of medical biological research, and particularly relates to a construction method of a spontaneous emphysema mouse model. The invention relates to a method for constructing a spontaneous emphysema mouse model, which comprises the following steps: when a Muc1 gene whole body knockout mouse naturally senility for 3-18 months to form spontaneous emphysema and / or a Muc1 type 2 alveolar epithelial cell knockout mouse is 6-8 weeks old, injecting tamoxifen into the intraperitoneal cavity of the mouse to induce knockout. According to the invention, the Muc1 gene knockout mouse is used for constructing a spontaneous emphysema mouse model product for the first time; the related products comprise construction schemes, application transformation and the like of a spontaneous emphysema model generated by Muc1 whole body knockout mouse (Muc1- / -) along with age increase and a spontaneous emphysema model generated by Muc1 type 2 alveolar epithelial cell knockout (Muc1AT2- / -) mouse induced by intraperitoneal injection tamoxifen along with age increase. The invention proves that the spontaneous emphysema model is successfully constructed.

The invention discloses a construction method of an animal model for combined induction and exacerbation of asthma. The method comprises the following steps: injecting ovalbumin or dermatophagoides pteronyssinus extract into an intraperitoneal cavity for sensitization; aerosol inhalation of allergen is carried out for airway re-exposure; in the aggravating stage, pathogenic microorganisms such as pseudomonas aeruginosa, aspergillus fumigatus or respiratory syncytial virus are given and exposed to 500 mu g / m PM2.5 aerosol; lung tissue and bronchoalveolar lavage fluid are then detected. The established model shows that the airway resistance is obviously enhanced and persistent, the mucous thrombus formation rate is greater than 50%, the smooth muscle is obviously thickened, and the model is accompanied by eosinophilic granulocyte and neutrophil infiltration and high expression of various inflammatory factors. The model is good in stability and high in repeatability, can truly simulate clinical asthma acute exacerbation and steroid insensitive characteristics, and provides a platform for asthma mechanism research and new drug screening.

The application belongs to the technical field of medicine and the technical field of brain degenerative diseases, and particularly relates to application of a PHGDH inhibitor NCT-503 in preparation of a medicine for preventing and treating Parkinson's disease, and verifies that specific inhibition of PHGDH can inhibit nerve inflammation in the brain substantia nigra region in vivo, reduce death of dopaminergic neurons, and thus relieve occurrence and development of Parkinson's disease; acute Parkinson's disease model mice are constructed by intraperitoneal injection of MPTP, and it is found that intraperitoneal injection treatment of NCT-503 can effectively reduce MPTP-induced nerve inflammation and reduce death of dopaminergic neurons. In conclusion, it is found for the first time that use of NCT-503 to inhibit PHGDH activity can significantly inhibit MPTP-induced nerve inflammation and reduce death of dopaminergic neurons, which provides an important theoretical basis for clinical application of NCT-503, and also provides a new idea for medicine research and development and screening for treating Parkinson's disease.

The invention discloses an application of an LCN2 protein. The application comprises the following applications: a, an application in preparation of a medicine for improving the plasticity of a visual cortex; b, application in preparation of drugs for treating visual cortex injury related diseases; the administration mode of the medicine is peripheral administration. The invention also discloses a peripherally administered LCN2 protein medicine, which comprises the LCN2 protein and a pharmaceutically acceptable carrier or auxiliary material, the peripheral administration of the LCN2 protein drug can improve the plasticity of the visual cortex and can treat visual cortex injury related diseases. According to the invention, the LCN2 protein is taken as an active ingredient, and a peripheral administration mode of intraperitoneal injection is adopted, so that the LCN2 protein can recover the nearly disappeared eye dominant plasticity of an adult individual, and a new way is provided for treating diseases related to visual cortex injury.

The invention provides an application of alkaloid bicuculline in preparation of a medicine for preventing and / or treating hepatic fibrosis diseases and hepatic inflammation, and also provides an application of bicuculline in preparation of an inflammatory factor expression inhibitor and an application of bicuculline in preparation of a Toll-like receptor 4 signal channel inhibitor. 7.5 mu g / mL of bicuculline can be used for relieving the activation of hepatic stellate cells induced by TGF-beta1, remarkably reducing the expression of alpha-SMA and COL1A1, and reducing the expression of MyD88 and NF-kB as well as downstream inflammatory factors IL-6, IL-1beta and TNF-alpha in a TLR4 / MyD88 / NF-kB signal channel. By intraperitoneal injection treatment of 0.6 mg / kg of bicuculline, the liver morphology in a fibrosis model can be remarkably improved, the levels of ALT and AST in serum can be remarkably reduced, and collagen deposition and expression of alpha-SMA and COL1A1 in the liver can be remarkably reduced.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The invention discloses application of gaboxadol or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating liver fibrosis diseases, and belongs to the technical field of biological medicines, and research shows that the compound can influence collagen fiber crosslinking through targeted inhibition of the function of prolyl-4-hydroxylase a1 (prolyl-4-hydroxylase alpha 1, P4ha1), so that the anti-fibrosis effect is achieved. The invention further discloses an application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases, and the application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases and the application of the gaboxadol or the pharmaceutically acceptable salt thereof in preparation of the medicine for treating the liver fibrosis diseases. In a carbon tetrachloride induced mouse hepatic fibrosis model, the content of hydroxyproline and collagen deposition in I-type collagen molecules of the liver can be remarkably reduced by injecting the gaboxadol hydrochloride into the intraperitoneal cavity, and the hardness of the liver is reduced. A surface plasma resonance experiment proves that the probe has specific binding capacity with P4ha1. Toxicity experiments show that the compound is good in safety under the effective dosage. Therefore, the invention provides a new drug candidate and a theoretical basis for the treatment of hepatic fibrosis.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

This invention discloses a live attenuated vaccine for the prevention of Toxoplasma gondii infection, the active ingredient of which is the tachyzoite of the Toxoplasma gondii RHΔpCaBp1 gene knockout strain. This invention prepares a live attenuated RHΔpCaBp1 vaccine that can be used to prevent Toxoplasma gondii infection in intermediate hosts. Immunization with this live attenuated vaccine, containing 100 Toxoplasma gondii RHΔpCaBp1 tachyzoites, via intraperitoneal injection, showed safety in mice after three immunizations, and demonstrated 100% protection against low-dose virulent strains (intraperitoneal injection of 100 and 500 RH tachyzoites) in the model intermediate host.

The invention belongs to the technical field of biological appliances for medical research, and particularly relates to a urinary surgery CP / CPPS model and a modeling method thereof. The modeling method comprises the following steps: (1) preparing prostate homogenate: taking rats of 4 months old, stripping prostate tissues under a sterile condition after the rats are killed, and grinding or homogenizing to prepare an injection suspension; (2) preparing a vaccine intraperitoneal injection: dissolving the inactivated vaccine freeze-dried powder into aluminum hydroxide gel normal saline to prepare the vaccine intraperitoneal injection; (3) injection of molding liquid: after anesthetizing the mouse, subcutaneously injecting prostate homogenate suspension, and intraperitoneally injecting vaccine intraperitoneal injection; and repeating the injection step until the mouse CP / CPPS model is formed. The modeling material disclosed by the invention can be conveniently purchased, the modeling material has common phenotypes of emotional abnormalities such as pain sensitization, anxiety, depression and the like of chronic pain after being molded, the phenotypes after modeling can be maintained for at least 90 days and can exceed half a year at most, the success rate of single-batch modeling is high, and the case fatality rate is low.

The invention discloses an application of a fibroblast growth factor 2 in preparation of a medicine for preventing and / or treating calcium oxalate kidney stone, and breaks through the technical prejudice that FGF-2 mainly promotes renal fibrosis in the prior art. It is found and proved for the first time that exogenous supplement FGF-2 can play a significant therapeutic effect in a calcium oxalate kidney stone model. Animal experiments prove that through intraperitoneal injection of FGF-2 (0.1 mg / kg / day), calcium salt crystal deposition in kidney tissue can be effectively reduced (Von Kossa dyeing verification), structural damage of renal tubular epithelial cells is relieved, inflammatory response is inhibited (HE dyeing verification), and meanwhile the serum creatinine and urea nitrogen level is remarkably improved. The invention provides a brand new molecular target and drug strategy for treatment of kidney stone, can be used as an effective auxiliary scheme of the existing physical lithotripsy technology, and reduces the risk of stone residue and recurrence.

The application provides a method for constructing a mouse model of mitochondrial myopathy with a Lars2 gene deletion and application thereof, a first Lars2 flox / flox mouse is obtained by crossing an Acta1 ER‑Cre mouse with an Acta1 ER‑Cre -Lars2 flox / flox mouse; in the second step, the above mouse reaches 4 weeks of age, and tamoxifen 70-80 mg / kg is used for continuous intraperitoneal injection for 5 days; in the third step, 4 weeks later, tamoxifen 45-55 mg / kg is used for continuous intraperitoneal injection for 5 days; in the fourth step, the Acta1 ER‑Cre -Lars2 flox / flox mouse reaches 12-13 weeks of age, and skeletal muscle Lars2 protein deletion occurs, and skeletal muscle atrophy occurs obviously at 16 weeks of age, thereby obtaining a mouse model of mitochondrial myopathy with a Lars2 gene deletion.

The application provides application of N-acyl dopamine family lipids in prevention and treatment of drug-induced Parkinson's disease motor complications, and belongs to the field of biological medicine. The application first proposes that the NADs compound can be used as a levodopa companion drug for preventing or treating levodopa-induced dyskinesia. The application takes 6-hydroxydopamine intracerebral injection and intraperitoneal injection of levodopa of an LID animal model as a research object, and studies the effect of NADs on improving LID. The results show that the NADs of the application can significantly improve the drug-induced PD motor complications LID, and it is proved that the NADs compound can be used as a companion drug to assist levodopa in treating PD.

The invention discloses application of ISCA2 in preparation of drugs for preventing and treating peritoneal fibrosis and related products and methods, relates to the technical field of biological medicines, and is characterized in that the application of ISCA2 protein in preparation of drugs for preventing and / or treating peritoneal fibrosis is provided. The invention provides a brand new application of the ISCA2. Experiments prove that the expression of the ISCA2 protein in peritoneal tissues of mice is inhibited in a high-glucose environment, and the activity of the iron-sulfur cluster enzyme can be promoted by injecting the ISCA2 adeno-associated virus into the peritoneal cavity of the mice to over-express the ISCA2 protein, so that the peritoneal fibrosis condition is improved; based on experimental results, it can be known that the overexpressed ISCA2 can play a role in treating peritoneal fibrosis, and therefore the ISCA2 has a good application prospect in the field of preparation of related drugs.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

The invention relates to an inflammatory environment induced overexpression 1L-10 engineered macrophage and a construction method and application thereof, and belongs to the field of biomedicine.The construction method includes the steps that a recombinant plasmid for expressing IL-10 is constructed with a genetic engineering method, and an RAW264.7 macrophage is jointly transfected with the constructed recombinant plasmid for expressing IL-10 and a Cas9 plasmid, so that the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained, and the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained. According to the method, the IL-10 gene is used for replacing the position of the IL-1 gene in the RAW264.7 macrophage, so that the RAW264.7 macrophage can express IL-10 under the induction of an inflammatory environment, the constructed engineered macrophage is injected into the abdominal cavity of a colitis model mouse in an intraperitoneal injection manner, the macrophage is positioned to the colitis disease part and secretes an anti-inflammatory cytokine IL-10 due to the inflammatory chemotaxis of the macrophage, and the anti-inflammatory cytokine IL-10 is obtained. The effect of relieving intestinal inflammation is achieved. According to the invention, the development of ulcerative colitis treatment technology is facilitated, and the application of a macrophage-based cell treatment method in treatment of digestive system diseases is promoted.

This invention provides a method for constructing a liver injury model in largemouth bass and its application, belonging to the field of aquatic pharmaceuticals. The construction method includes the following steps: 1) Intraperitoneal injection of thioacetamide into largemouth bass at a dose of 100-150 mg / kg body weight, once; 2) Obtaining the model after 6-15 days of conventional rearing. This invention enables model creation with a short cycle, low cost, good reproducibility, and simple operation, solving the problem of high animal mortality in existing technologies for creating acute liver injury models.